The US Food and Drug Administration's biosimilar user fee program booked a substantial loss in fiscal year 2018 compared to estimates, but the agency is not worried about its ongoing health.
Cash collections were estimated to be $40.2m that year, but the agency only received $29.2m, according to program financial data discussed 7 June during an FDA public meeting on user fee program financial transparency and efficiency
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?